DiaMedica Therapeutics (DMAC) Competitors $5.17 -0.17 (-3.18%) (As of 11:40 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends DMAC vs. IMNM, AUTL, ERAS, EOLS, KURA, RAPP, PRTA, TYRA, CRGX, and AVXLShould you be buying DiaMedica Therapeutics stock or one of its competitors? The main competitors of DiaMedica Therapeutics include Immunome (IMNM), Autolus Therapeutics (AUTL), Erasca (ERAS), Evolus (EOLS), Kura Oncology (KURA), Rapport Therapeutics (RAPP), Prothena (PRTA), Tyra Biosciences (TYRA), CARGO Therapeutics (CRGX), and Anavex Life Sciences (AVXL). These companies are all part of the "pharmaceutical products" industry. DiaMedica Therapeutics vs. Immunome Autolus Therapeutics Erasca Evolus Kura Oncology Rapport Therapeutics Prothena Tyra Biosciences CARGO Therapeutics Anavex Life Sciences DiaMedica Therapeutics (NASDAQ:DMAC) and Immunome (NASDAQ:IMNM) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, community ranking, analyst recommendations, media sentiment, dividends, valuation, risk, profitability and institutional ownership. Which has preferable earnings & valuation, DMAC or IMNM? DiaMedica Therapeutics has higher earnings, but lower revenue than Immunome. DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Immunome, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDiaMedica TherapeuticsN/AN/A-$19.38M-$0.56-9.23Immunome$14.02M60.55-$106.81M-$8.11-1.68 Does the MarketBeat Community favor DMAC or IMNM? DiaMedica Therapeutics received 62 more outperform votes than Immunome when rated by MarketBeat users. However, 73.81% of users gave Immunome an outperform vote while only 62.84% of users gave DiaMedica Therapeutics an outperform vote. CompanyUnderperformOutperformDiaMedica TherapeuticsOutperform Votes9362.84% Underperform Votes5537.16% ImmunomeOutperform Votes3173.81% Underperform Votes1126.19% Does the media prefer DMAC or IMNM? In the previous week, Immunome had 4 more articles in the media than DiaMedica Therapeutics. MarketBeat recorded 5 mentions for Immunome and 1 mentions for DiaMedica Therapeutics. DiaMedica Therapeutics' average media sentiment score of 1.89 beat Immunome's score of 0.95 indicating that DiaMedica Therapeutics is being referred to more favorably in the media. Company Overall Sentiment DiaMedica Therapeutics Very Positive Immunome Positive Do institutionals & insiders believe in DMAC or IMNM? 10.1% of DiaMedica Therapeutics shares are held by institutional investors. Comparatively, 44.6% of Immunome shares are held by institutional investors. 7.2% of DiaMedica Therapeutics shares are held by company insiders. Comparatively, 8.6% of Immunome shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Which has more risk & volatility, DMAC or IMNM? DiaMedica Therapeutics has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500. Comparatively, Immunome has a beta of 1.83, suggesting that its share price is 83% more volatile than the S&P 500. Is DMAC or IMNM more profitable? DiaMedica Therapeutics has a net margin of 0.00% compared to Immunome's net margin of -3,014.59%. DiaMedica Therapeutics' return on equity of -43.67% beat Immunome's return on equity.Company Net Margins Return on Equity Return on Assets DiaMedica TherapeuticsN/A -43.67% -40.81% Immunome -3,014.59%-48.63%-41.62% Do analysts rate DMAC or IMNM? DiaMedica Therapeutics currently has a consensus price target of $7.00, suggesting a potential upside of 35.40%. Immunome has a consensus price target of $28.83, suggesting a potential upside of 112.01%. Given Immunome's higher possible upside, analysts plainly believe Immunome is more favorable than DiaMedica Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score DiaMedica Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Immunome 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryImmunome beats DiaMedica Therapeutics on 9 of the 16 factors compared between the two stocks. Ad Porter & CompanyThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally critical role in supporting the most revolutionary technology the world’s ever seen… artificial intelligence. And without it, the entire AI industry would collapse. You must read this new presentation from Porter Stansberry. Get DiaMedica Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for DMAC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart DMAC vs. The Competition Export to ExcelMetricDiaMedica TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$221.07M$6.73B$5.20B$8.97BDividend YieldN/A7.94%5.23%4.04%P/E Ratio-9.234.7285.7113.39Price / SalesN/A352.931,469.4286.49Price / CashN/A22.8835.2935.09Price / Book3.835.604.914.96Net Income-$19.38M$151.32M$117.36M$224.10M7 Day Performance1.77%3.14%2.75%2.01%1 Month Performance21.65%-1.67%1.71%9.79%1 Year Performance99.61%31.88%36.01%29.97% DiaMedica Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)DMACDiaMedica Therapeutics2.4775 of 5 stars$5.17-3.2%$7.00+35.4%+106.2%$221.07MN/A-9.2320Positive NewsGap DownIMNMImmunome2.0523 of 5 stars$14.07+3.8%$28.83+104.9%+80.5%$878.21M$10.13M-1.7040AUTLAutolus Therapeutics3.9286 of 5 stars$3.30-0.6%$10.15+207.6%-22.2%$878.10M$1.70M-2.74330Positive NewsGap UpERASErasca3.1948 of 5 stars$3.06+7.0%$5.90+92.8%+93.4%$865.15MN/A-3.46126Positive NewsGap DownEOLSEvolus4.2514 of 5 stars$13.56-0.9%$23.00+69.6%+38.6%$858.62M$202.09M-15.04170Positive NewsGap DownKURAKura Oncology4.298 of 5 stars$11.03-0.1%$29.38+166.3%+12.4%$857.69MN/A-4.68142RAPPRapport Therapeutics2.4216 of 5 stars$23.31+2.1%$35.00+50.2%N/A$852.59MN/A0.00N/AShort Interest ↓Lockup ExpirationGap UpPRTAProthena1.9907 of 5 stars$15.54-4.1%$61.86+298.1%-57.0%$836.21M$91.37M-6.54173Positive NewsTYRATyra Biosciences2.7071 of 5 stars$16.12+2.8%$31.00+92.3%+36.6%$815.72MN/A-9.7420Positive NewsCRGXCARGO Therapeutics1.8452 of 5 stars$17.56-3.4%$30.33+72.7%+9.9%$808.25MN/A-4.15116AVXLAnavex Life Sciences3.7203 of 5 stars$9.47+0.1%$43.00+354.1%+23.1%$803.06MN/A-18.9240 Related Companies and Tools Related Companies Immunome Alternatives Autolus Therapeutics Alternatives Erasca Alternatives Evolus Alternatives Kura Oncology Alternatives Rapport Therapeutics Alternatives Prothena Alternatives Tyra Biosciences Alternatives CARGO Therapeutics Alternatives Anavex Life Sciences Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:DMAC) was last updated on 12/3/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredIs NVDA a sell? Buy this stock instead before Dec 3After months of speculation that Nvidia was "cooling off..." and "running out of steam..." The company is m...Chaikin Analytics | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DiaMedica Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share DiaMedica Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
